黃茗沂

標靶藥物作為表皮生長因子接受器突變之肺腺癌晚期第一線治療之成效分析 = Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation by: 黃茗沂 (書目-語言資料,印刷品)